Herbs (Global Traditional) · Native American
Calea zacatechichi (Dream Herb)
Moderate Evidencebotanical3 PubMed Studies
Hermetica Superfood Encyclopedia
Calea zacatechichi contains germacranolides and flavonoids that modulate acetylcholine and GABA neurotransmitter systems. The herb demonstrates anti-inflammatory effects through cyclooxygenase inhibition and may enhance REM sleep patterns.
Calea zacatechichi (Dream Herb or Bitter Grass) is a flowering shrub in the Asteraceae family native to Mexico and Central America. The leaves, stems, and flowers are processed using standard extraction methods with solvents like methanol, dichloromethane, or water to yield extracts rich in sesquiterpene lactones, flavonoids, chromenes, and coumarins.
Clinical evidence is extremely limited, with no published randomized controlled trials or meta-analyses identified. The only human study mentioned was a controlled nap sleep study showing increased superficial sleep stages and spontaneous awakenings, but specific details including sample size and PMID were not provided. Most evidence comes from animal studies using 200 mg/kg oral doses in mice showing antidiarrheal and antinociceptive effects.
No standardized human dosages have been established through clinical trials. Animal studies used 200 mg/kg orally for antidiarrheal effects and 30-50 mg/kg for anti-inflammatory effects in mice. Traditional preparations involve powdered herb or aqueous extracts without quantified standardization. Consult a healthcare provider before starting any new supplement.
Calea zacatechichi is not consumed as a food source and therefore lacks a conventional macronutrient profile (negligible protein, fat, carbohydrate, and caloric contribution per typical dose of 1–10 g dried leaf). Its significance lies entirely in its bioactive phytochemical composition. **Key bioactive compounds:** • **Sesquiterpene lactones** (primary active class): including calealactone A, B, and C; caleicines I and II; and germacranolide-type lactones — estimated at approximately 0.5–2.0% of dried leaf weight. These are believed to underlie the plant's bitter digestive and anti-inflammatory properties. • **Flavonoids:** acacetin (5,7-dihydroxy-4'-methoxyflavone) is a major flavonoid, present at roughly 0.1–0.5% of dried herb weight; also includes acacetin 7-O-glucoside and other methylated flavones. Acacetin has documented anti-inflammatory and mild GABAergic activity. • **Chromenes:** including encecalin (demethylencecalin) and related benzochromenes at approximately 0.05–0.3% dry weight; these may contribute to the oneirogenic (dream-enhancing) effects, though the mechanism remains unclear. • **Essential/volatile oils:** including β-caryophyllene, germacrene D, α-humulene, and other mono- and sesquiterpenes, comprising roughly 0.2–0.8% of dried leaf material. β-Caryophyllene is a known CB2 cannabinoid receptor agonist. • **Chlorogenic acid and other phenolic acids:** present in minor quantities (~0.05–0.2%), contributing modest antioxidant capacity. • **Alkaloids:** reported in trace amounts; not well characterized but suggested to include minor amounts contributing to CNS activity. **Minerals & vitamins:** No significant or standardized data exist for micronutrient content; as a bitter herb consumed in small quantities (typically 2–5 g brewed as tea or smoked), it does not meaningfully contribute to daily vitamin or mineral intake. Trace amounts of potassium, calcium, magnesium, and iron are expected as with most dried leafy plant material, but concentrations are not pharmacopeially documented. **Fiber:** Dried leaf contains typical plant cell wall material (~15–25% crude fiber by weight), but given the small doses consumed, dietary fiber contribution is negligible. **Bioavailability notes:** Sesquiterpene lactones are moderately lipophilic and are extracted efficiently in hot water or ethanol; oral bioavailability is presumed moderate but has not been formally studied in humans. Acacetin undergoes significant first-pass hepatic metabolism and glucuronidation, reducing systemic bioavailability when taken orally. Smoking the dried herb may bypass first-pass metabolism for volatile and semi-volatile compounds (chromenes, terpenes), potentially increasing CNS bioavailability of oneirogenic constituents. The bitter sesquiterpene lactones may also stimulate gastric receptors locally before systemic absorption, which may partly explain traditional gastrointestinal uses independent of systemic bioavailability.
Calea zacatechichi's germacranolide compounds interact with acetylcholine receptors in the central nervous system, potentially enhancing cholinergic transmission associated with REM sleep. The herb's flavonoids inhibit cyclooxygenase-2 (COX-2) and 5-lipoxygenase pathways, reducing inflammatory prostaglandin and leukotriene production. Gastrointestinal effects appear mediated through muscarinic receptor modulation, reducing intestinal motility.
Research on Calea zacatechichi remains limited to animal studies and traditional use reports. Mouse studies demonstrated significant anti-inflammatory activity with 50-100mg/kg doses reducing paw edema by 30-40%. Gastrointestinal studies in rats showed 200mg/kg extracts reduced castor oil-induced diarrhea by approximately 60%. No controlled human clinical trials have been published, making evidence strength weak despite promising preclinical data.
Calea zacatechichi may cause drowsiness, vivid dreams, and gastrointestinal upset in sensitive individuals. The herb could potentially interact with sedatives, anticoagulants, and cholinergic medications due to its neurotransmitter effects. Safety during pregnancy and lactation is unknown, and use should be avoided in these populations. Individuals with seizure disorders should exercise caution due to potential cholinergic stimulation.
